Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGD with Xenograft for Ridge Augmentation
NCT06585852Recruiting
- Sponsor
- Al-Azhar University
- Start
- Aug 2023
- Primary completion
- Sep 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised trial of arginylglycylaspartic acid in alveolar ridge atrophy (2 arms), sponsored by Al-Azhar University. Primary endpoint: Implant Stability Quotient. Started Aug 2023; status: recruiting.
02
Drugs
arginylglycylaspartic acid
03
Conditions
alveolar ridge atrophy
Beyond the preview
Go deeper on NCT06585852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585852.